Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors
Phase 1
20 Years
N/A
20 Years
N/A
Not Enrolling
Both
Cancer
Both
Cancer
Trial Information
Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors
Inclusion Criteria:
- Subjects with advanced or metastatic solid tumors for whom the standard of care is
ineffective or inappropriate, with adequate kidney, liver and cardiac function.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To determine the Maximum Tolerated Dose, the Dose Limiting Toxicity of BMS-690514
Outcome Time Frame:
administered orally every day 28 days
Safety Issue:
Yes
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
United States: Food and Drug Administration
Study ID:
CA187-006
NCT ID:
NCT00516451
Start Date:
November 2007
Completion Date:
July 2008
Related Keywords:
- Cancer
Name | Location |
|---|
